Rachel M. Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rachel M. Lee has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Sheila N. Garland
Department of Psychology Memorial University St. John's Newfoundland and Labrador Canada
6 shared publications - Jennifer Donnan
Memorial University of Newfoundland
2 shared publications - Joshua A. Rash
Department of Psychology, Memorial University of Newfoundland, St. John’s, Newfoundland and Labrador, Canada
2 shared publications - Nick Harris
Department of Psychology, Memorial University of Newfoundland, St. John’s, Canada
2 shared publications - Gregory Cerallo
Sidekick Interactive, Montreal, QC, Canada
1 shared publication - Joshua Tulk
Department of Psychology, Faculty of Science, Memorial University, St. John’s, Canada
1 shared publication
Latest Publications
- 7 October 2026
- Published by Springer Nature in Current Sleep Medicine Reports
- Vol. 12 (1) , 48
Population-Specific Applications of Digital CBT-I: Evidence, Adaptations, and Emerging Directions
- 7 October 2026
- Published by Springer Nature in Current Sleep Medicine Reports
- Vol. 12 (1) , 48
Population-Specific Applications of Digital CBT-I: Evidence, Adaptations, and Emerging Directions
- Open Access
- 23 September 2025
- Published by JMIR Publications Inc. in JMIR Cancer
- Vol. 11, e74387
Development of a Mobile App (iCANSleep) to Treat Insomnia in Cancer Survivors: User-Centered Design Study
Background: Insomnia affects the quality of life and health outcomes of cancer survivors. Cognitive behavioral therapy for insomnia (CBT-I) is an effective treatment for insomnia among cancer survivors, but it is not readily accessible due to the limited number of trained providers and the difficulties in providing care across wide geographical areas. Mobile health (mHealth) technologies represent a promising solution; however, these technologies are not tailored to the unique needs of cancer survivors. Objective: This study aimed to understand the needs and preferences of cancer survivors and test the usability of an evidence-based CBT-I smartphone app called iCANSleep that will be tailored and accessible to cancer survivors. Methods: A user-centered design (UCD) approach was applied, and cancer survivors were actively engaged in the app’s design, usability testing, and prototype refinement. In phase 1, semistructured interviews were conducted with a purposive sample of cancer survivors (n=20) to inform the design of the app and its content. In phase 2, iterative low- (n=8) and high-fidelity (n=7) usability testing was conducted with participants until no further recommendations for change were suggested. Results: Users suggested several defining characteristics, features, and desired functionalities, including a user-friendly and evidence-based design. They saw increased accessibility and simplicity as advantages of a mobile app but expressed some concerns about data security and losing the accountability that comes with in-person treatment. User testing highlighted the preference for images of real people and diverse stories over graphics and animated videos, and offered suggestions for enhanced navigation. The first iteration of the app was developed using the information gained during the needs assessment and usability testing. Feedback was integrated into the final prototype of the iCANSleep app, which will be tested for feasibility, acceptability, and efficacy. Conclusions: Cancer survivors desire an insomnia treatment app that is simple, user-friendly, evidence-based, convenient, and secure. The iCANSleep app represents the merging of mHealth principles and best practices with evidence-based insomnia care, allowing for an intervention with minimal access barriers related to cost, geography, and provider availability. Feasibility, acceptability, and efficacy of the intervention will be maximized by following a UCD framework involving the engagement of end users at every design stage.
- 23 September 2025
- Published by JMIR Publications Inc. in JMIR Cancer
- Vol. 11, e74387
Open AccessDevelopment of a Mobile App (iCANSleep) to Treat Insomnia in Cancer Survivors: User-Centered Design Study
Background: Insomnia affects the quality of life and health outcomes of cancer survivors. Cognitive behavioral therapy for insomnia (CBT-I) is an effective treatment for insomnia among cancer survivors, but it is not readily accessible due to the limited number of trained providers and the difficulties in providing care across wide geographical areas. Mobile health (mHealth) technologies represent a promising solution; however, these technologies are not tailored to the unique needs of cancer survivors. Objective: This study aimed to understand the needs and preferences of cancer survivors and test the usability of an evidence-based CBT-I smartphone app called iCANSleep that will be tailored and accessible to cancer survivors. Methods: A user-centered design (UCD) approach was applied, and cancer survivors were actively engaged in the app’s design, usability testing, and prototype refinement. In phase 1, semistructured interviews were conducted with a purposive sample of cancer survivors (n=20) to inform the design of the app and its content. In phase 2, iterative low- (n=8) and high-fidelity (n=7) usability testing was conducted with participants until no further recommendations for change were suggested. Results: Users suggested several defining characteristics, features, and desired functionalities, including a user-friendly and evidence-based design. They saw increased accessibility and simplicity as advantages of a mobile app but expressed some concerns about data security and losing the accountability that comes with in-person treatment. User testing highlighted the preference for images of real people and diverse stories over graphics and animated videos, and offered suggestions for enhanced navigation. The first iteration of the app was developed using the information gained during the needs assessment and usability testing. Feedback was integrated into the final prototype of the iCANSleep app, which will be tested for feasibility, acceptability, and efficacy. Conclusions: Cancer survivors desire an insomnia treatment app that is simple, user-friendly, evidence-based, convenient, and secure. The iCANSleep app represents the merging of mHealth principles and best practices with evidence-based insomnia care, allowing for an intervention with minimal access barriers related to cost, geography, and provider availability. Feasibility, acceptability, and efficacy of the intervention will be maximized by following a UCD framework involving the engagement of end users at every design stage.
- Open Access
- 10 May 2025
- Published by Springer Nature in Sleep Science and Practice
- Vol. 9 (1) , 1-11
Recording and reporting of adverse events during a randomized controlled trial of cognitive behavioural therapy for insomnia (CBT-I) among cancer survivors
Sleep disturbances are one of the biggest barriers to resuming normal functioning following cancer treatment. Cognitive behavioral therapy for insomnia (CBT-I) has demonstrated efficacy in cancer survivors but few studies have recorded adverse events (AEs) that occur during treatment. The purpose of this study was to report the prevalence, severity, and attribution of AEs during CBT-I with cancer survivors. Cancer survivors from Atlantic Canada with insomnia and comorbid cognitive impairment were recruited to participate in a randomized controlled trial of CBT-I. Participants reported the prevalence, severity, and attribution of AEs at mid-treatment (4 weeks) and post-treatment (8 weeks). The likeliness of AEs being related to treatment was also rated by an independent clinician. Of the 122 cancer survivors who completed treatment (Mage = 60.3, 77.9% women), 72 reported a total of 197 AEs. At mid-treatment, participants reported 113 AEs, but only 11 were rated as being attributed to the intervention. At post-treatment, participants did not report any AEs attributed to the intervention. An independent rater attributed more AEs to the treatment than the participants at both time points (4 weeks: 16 vs. 11, 8 weeks: 1 vs. 0). Gender (p = .014) and pre-treatment anxiety (p < .001) were associated with reporting an AE. CBT-I is a safe treatment that is well-tolerated by cancer survivors. The majority of participants did not experience AEs that could be attributed to the treatment. Clinicians should continue to recommend CBT-I as the first-line treatment for cancer survivors experiencing insomnia symptoms. This study is a secondary analysis of a randomized controlled trial titled ‘Addressing Cancer Treatment-Related Insomnia Online in Atlantic Canada (ACTION) study’ ( https://www.clinicaltrials.gov/search?cond=NCT04026048 identifier: NCT04026048).
- 10 May 2025
- Published by Springer Nature in Sleep Science and Practice
- Vol. 9 (1) , 1-11
Open AccessRecording and reporting of adverse events during a randomized controlled trial of cognitive behavioural therapy for insomnia (CBT-I) among cancer survivors
Sleep disturbances are one of the biggest barriers to resuming normal functioning following cancer treatment. Cognitive behavioral therapy for insomnia (CBT-I) has demonstrated efficacy in cancer survivors but few studies have recorded adverse events (AEs) that occur during treatment. The purpose of this study was to report the prevalence, severity, and attribution of AEs during CBT-I with cancer survivors. Cancer survivors from Atlantic Canada with insomnia and comorbid cognitive impairment were recruited to participate in a randomized controlled trial of CBT-I. Participants reported the prevalence, severity, and attribution of AEs at mid-treatment (4 weeks) and post-treatment (8 weeks). The likeliness of AEs being related to treatment was also rated by an independent clinician. Of the 122 cancer survivors who completed treatment (Mage = 60.3, 77.9% women), 72 reported a total of 197 AEs. At mid-treatment, participants reported 113 AEs, but only 11 were rated as being attributed to the intervention. At post-treatment, participants did not report any AEs attributed to the intervention. An independent rater attributed more AEs to the treatment than the participants at both time points (4 weeks: 16 vs. 11, 8 weeks: 1 vs. 0). Gender (p = .014) and pre-treatment anxiety (p < .001) were associated with reporting an AE. CBT-I is a safe treatment that is well-tolerated by cancer survivors. The majority of participants did not experience AEs that could be attributed to the treatment. Clinicians should continue to recommend CBT-I as the first-line treatment for cancer survivors experiencing insomnia symptoms. This study is a secondary analysis of a randomized controlled trial titled ‘Addressing Cancer Treatment-Related Insomnia Online in Atlantic Canada (ACTION) study’ ( https://www.clinicaltrials.gov/search?cond=NCT04026048 identifier: NCT04026048).
- 28 May 2024
- Published by Taylor & Francis in Behavioral Sleep Medicine
- Vol. 22 (5) , 754-769
A Cross Sectional Survey of Factors Related to Cannabis Use as a Sleep Aid Among Canadian Cancer Survivors
Poor sleep is a common side effect of cancer. Cannabis is increasingly used to manage cancer treatment-related symptoms, including sleep. This study investigated factors related to cannabis use for sleep among Canadian cancer survivors. Adult Canadian cancer survivors (N = 940) were recruited via the Angus Reid Institute and completed an online, cross-sectional survey. Univariate and multiple binomial logistic regression models identified factors associated with cannabis use for sleep. Of the participants (Mage = 64.5 yrs; Women = 51.1%; White = 92.9%), 25.1% (n = 236) currently use cannabis for sleep. Participants were at greater odds of using cannabis for sleep if they identified as a gender other than man or woman (AOR = 11.132), were diagnosed with multiple medical conditions (2:AOR = 1.988; 3+:AOR = 1.902), two psychological conditions (AOR = 2.171), multiple sleep disorders (AOR = 2.338), insomnia (AOR = 1.942), bone (AOR = 6.535), gastrointestinal (AOR = 4.307), genitourinary (AOR = 2.586), hematological (AOR = 4.739), or an unlisted cancer (AOR = 3.470), received hormone therapy only (AOR = 3.054), drink heavily (AOR = 2.748), or had mild insomnia (AOR = 1.828). Older participants (AOR=.972) and those with sleep apnea were less likely to use cannabis for sleep (AOR=.560). Given its prevalence, research is needed to understand how factors associated with cannabis use as a sleep aid among Canadian cancer survivors may influence its use and effectiveness and whether these factors are barriers to accessing evidence-based treatments.
- 28 May 2024
- Published by Taylor & Francis in Behavioral Sleep Medicine
- Vol. 22 (5) , 754-769
A Cross Sectional Survey of Factors Related to Cannabis Use as a Sleep Aid Among Canadian Cancer Survivors
Poor sleep is a common side effect of cancer. Cannabis is increasingly used to manage cancer treatment-related symptoms, including sleep. This study investigated factors related to cannabis use for sleep among Canadian cancer survivors. Adult Canadian cancer survivors (N = 940) were recruited via the Angus Reid Institute and completed an online, cross-sectional survey. Univariate and multiple binomial logistic regression models identified factors associated with cannabis use for sleep. Of the participants (Mage = 64.5 yrs; Women = 51.1%; White = 92.9%), 25.1% (n = 236) currently use cannabis for sleep. Participants were at greater odds of using cannabis for sleep if they identified as a gender other than man or woman (AOR = 11.132), were diagnosed with multiple medical conditions (2:AOR = 1.988; 3+:AOR = 1.902), two psychological conditions (AOR = 2.171), multiple sleep disorders (AOR = 2.338), insomnia (AOR = 1.942), bone (AOR = 6.535), gastrointestinal (AOR = 4.307), genitourinary (AOR = 2.586), hematological (AOR = 4.739), or an unlisted cancer (AOR = 3.470), received hormone therapy only (AOR = 3.054), drink heavily (AOR = 2.748), or had mild insomnia (AOR = 1.828). Older participants (AOR=.972) and those with sleep apnea were less likely to use cannabis for sleep (AOR=.560). Given its prevalence, research is needed to understand how factors associated with cannabis use as a sleep aid among Canadian cancer survivors may influence its use and effectiveness and whether these factors are barriers to accessing evidence-based treatments.
- 18 March 2024
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 32 (4) , 1-9
Early change in fatigue, insomnia, and cognitive impairment and symptom severity 3 years post-treatment in breast cancer survivors
Purpose Breast cancer is the most common form of cancer among Canadian women. Survivorship challenges include fatigue, sleep disturbance, and cognitive impairment. This study examined (1) symptom trajectory from diagnosis to 3 years; (2) whether symptom change in the first 4 months was associated with prolonged difficulties after 3 years; and (3) which factors were associated with deterioration in symptoms during the first 4 months. Methods This prospective observational cohort study examined 53 women (Mage = 58.6, 96.2% White, 67.9% stage I) with newly diagnosed breast cancer over 3 years. Women completed assessments before starting treatment, 4 months, and 3 years after diagnosis. Three-way repeated-measures ANOVAs evaluated symptom trajectories. A repeated-measures mediation analysis was performed to determine if change from pre-treatment to 4 months accounted for change from pre-treatment to 3 years. A series of between-subjects ANOVAs were used to determine what variables significantly differed by deterioration status. Results Perceived cognitive impairment and fatigue increased linearly from diagnosis to 3 years. Change in fatigue in the first 4 months fully accounted for its change over 3 years. Insomnia severity and sleep quality deteriorated from diagnosis to 4 months, but returned to pre-treatment levels at 3 years. Those whose fatigue and cognitive ability deteriorated during the first 4 months were younger. Conclusion Efforts to identify those who are at risk of experiencing fatigue, sleep disturbance, and cognitive impairment; monitor patients early after receiving a diagnosis; and provide targeted interventions may prevent long-term deterioration and improve well-being.
- 18 March 2024
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 32 (4) , 1-9
Early change in fatigue, insomnia, and cognitive impairment and symptom severity 3 years post-treatment in breast cancer survivors
Purpose Breast cancer is the most common form of cancer among Canadian women. Survivorship challenges include fatigue, sleep disturbance, and cognitive impairment. This study examined (1) symptom trajectory from diagnosis to 3 years; (2) whether symptom change in the first 4 months was associated with prolonged difficulties after 3 years; and (3) which factors were associated with deterioration in symptoms during the first 4 months. Methods This prospective observational cohort study examined 53 women (Mage = 58.6, 96.2% White, 67.9% stage I) with newly diagnosed breast cancer over 3 years. Women completed assessments before starting treatment, 4 months, and 3 years after diagnosis. Three-way repeated-measures ANOVAs evaluated symptom trajectories. A repeated-measures mediation analysis was performed to determine if change from pre-treatment to 4 months accounted for change from pre-treatment to 3 years. A series of between-subjects ANOVAs were used to determine what variables significantly differed by deterioration status. Results Perceived cognitive impairment and fatigue increased linearly from diagnosis to 3 years. Change in fatigue in the first 4 months fully accounted for its change over 3 years. Insomnia severity and sleep quality deteriorated from diagnosis to 4 months, but returned to pre-treatment levels at 3 years. Those whose fatigue and cognitive ability deteriorated during the first 4 months were younger. Conclusion Efforts to identify those who are at risk of experiencing fatigue, sleep disturbance, and cognitive impairment; monitor patients early after receiving a diagnosis; and provide targeted interventions may prevent long-term deterioration and improve well-being.
- 14 October 2023
- Published by Springer Nature in Journal of Cancer Survivorship
- Vol. 19 (1) , 386-396
A cross-sectional survey of the prevalence and patterns of using cannabis as a sleep aid in Canadian cancer survivors
Purpose Poor sleep is one of the most common side effects of cancer. It can persist for years beyond treatment and negatively impact quality of life and health. Cannabis is increasingly used to manage cancer treatment-related symptoms, including sleep. This study investigated the use and perceived effects of cannabis as a sleep aid in Canadian cancer survivors. Methods Adult Canadian cancer survivors (N = 1464) were recruited via the Angus Reid Institute and completed an online, cross-sectional survey including the Insomnia Severity Index and questions about cannabis use for sleep. Standard descriptive statistics, such as means, standard deviations, and ranges were produced for measured variables to assess the ways cancer survivors use cannabis for sleep. Frequencies were tabulated for categorical and ordinal variables. Results On average, participants (Mage = 61.1 years; Women = 50%: Men = 48%) received their cancer diagnosis 12.5 years prior. Of participants, 23.5% (n = 344) currently use cannabis as a sleep aid, with reported benefits including relaxation, reduced time to fall asleep, fewer nocturnal awakenings and improved sleep quality. Two thirds (68.3%, n = 235) only began using cannabis for sleep after their cancer diagnosis. Over a third of participants (36.3%, n = 125) use cannabis as a sleep aid every day. Among the 344, the most common other reasons for using cannabis were pain (31.4%, n = 108), recreational use (24.4%, n = 84), and anxiety (12.5%, n = 43). Conclusions Given the prevalence and potential impact, research is needed to examine the actual efficacy of cannabis as a sleep aid. Implications for cancer survivors It is important that cancer survivors have information on methods to help their sleep to avoid impairments to quality of life and health.
- 14 October 2023
- Published by Springer Nature in Journal of Cancer Survivorship
- Vol. 19 (1) , 386-396
A cross-sectional survey of the prevalence and patterns of using cannabis as a sleep aid in Canadian cancer survivors
Purpose Poor sleep is one of the most common side effects of cancer. It can persist for years beyond treatment and negatively impact quality of life and health. Cannabis is increasingly used to manage cancer treatment-related symptoms, including sleep. This study investigated the use and perceived effects of cannabis as a sleep aid in Canadian cancer survivors. Methods Adult Canadian cancer survivors (N = 1464) were recruited via the Angus Reid Institute and completed an online, cross-sectional survey including the Insomnia Severity Index and questions about cannabis use for sleep. Standard descriptive statistics, such as means, standard deviations, and ranges were produced for measured variables to assess the ways cancer survivors use cannabis for sleep. Frequencies were tabulated for categorical and ordinal variables. Results On average, participants (Mage = 61.1 years; Women = 50%: Men = 48%) received their cancer diagnosis 12.5 years prior. Of participants, 23.5% (n = 344) currently use cannabis as a sleep aid, with reported benefits including relaxation, reduced time to fall asleep, fewer nocturnal awakenings and improved sleep quality. Two thirds (68.3%, n = 235) only began using cannabis for sleep after their cancer diagnosis. Over a third of participants (36.3%, n = 125) use cannabis as a sleep aid every day. Among the 344, the most common other reasons for using cannabis were pain (31.4%, n = 108), recreational use (24.4%, n = 84), and anxiety (12.5%, n = 43). Conclusions Given the prevalence and potential impact, research is needed to examine the actual efficacy of cannabis as a sleep aid. Implications for cancer survivors It is important that cancer survivors have information on methods to help their sleep to avoid impairments to quality of life and health.